346 related articles for article (PubMed ID: 35581573)
1. MTHFD2 is a potential oncogene for its strong association with poor prognosis and high level of immune infiltrates in urothelial carcinomas of bladder.
Zhu L; Liu X; Zhang W; Hu H; Wang Q; Xu K
BMC Cancer; 2022 May; 22(1):556. PubMed ID: 35581573
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of POLR3G predicts poor prognosis in transitional cell carcinoma.
Liu X; Zhang W; Wang H; Lai CH; Xu K; Hu H
PeerJ; 2020; 8():e10281. PubMed ID: 33194434
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
Shi X; Peng X; Chen Y; Shi Z; Yue C; Zuo L; Zhang L; Gao S
Front Immunol; 2023; 14():1326509. PubMed ID: 38130721
[TBL] [Abstract][Full Text] [Related]
4. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
[TBL] [Abstract][Full Text] [Related]
5. TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle.
Jiang Y; Zhu C; Huang H; Huang G; Fu B; Xi X
BMC Cancer; 2023 Aug; 23(1):716. PubMed ID: 37528357
[TBL] [Abstract][Full Text] [Related]
6. PVT1 is a prognostic marker associated with immune invasion of bladder urothelial carcinoma.
Li P; Qiao G; Lu J; Ji W; Gao C; Qi F
Math Biosci Eng; 2022 Jan; 19(1):169-190. PubMed ID: 34902986
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance and immunoinfiltration analysis of genes associated with epithelial-mesenchymal transition and energy metabolism in bladder urothelial carcinoma.
Qiu Y; Ye W; Wang C; Zang J
Aging (Albany NY); 2023 Nov; 15(22):13312-13328. PubMed ID: 38015710
[TBL] [Abstract][Full Text] [Related]
8. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
[TBL] [Abstract][Full Text] [Related]
9. KLK6 Functions as an Oncogene and Unfavorable Prognostic Factor in Bladder Urothelial Carcinoma.
Zhao K; Gao M; Lin M
Dis Markers; 2022; 2022():3373851. PubMed ID: 36193495
[TBL] [Abstract][Full Text] [Related]
10. miR-628-5p is a Potential Novel Prognosis Biomarker, Associated with Immune Infiltration in Bladder Urothelial Carcinoma.
Huang H; Xu Q; Zhang Y; Zhou Y; Ma K; Luo Y
Curr Pharm Des; 2023; 29(31):2477-2488. PubMed ID: 37916623
[TBL] [Abstract][Full Text] [Related]
11. PRR11 is a prognostic biomarker and correlates with immune infiltrates in bladder urothelial carcinoma.
Ni W; Yi L; Dong X; Cao M; Zheng J; Wei Q; Yuan C
Sci Rep; 2023 Feb; 13(1):2051. PubMed ID: 36739300
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Investigation of Genes Associated with Cell Cycle Pathways for Prognosis and Immunotherapy in Bladder Urothelial Carcinoma.
Mi Y; Wang X
J Environ Pathol Toxicol Oncol; 2022; 41(3):1-12. PubMed ID: 35993952
[TBL] [Abstract][Full Text] [Related]
13. Prognosis and immune infiltration analysis of endoplasmic reticulum stress-related genes in bladder urothelial carcinoma.
Wang Y; Zhu H; Wang X
Front Genet; 2022; 13():965100. PubMed ID: 36186448
[No Abstract] [Full Text] [Related]
14. Construction and validation of a gene signature related to bladder urothelial carcinoma based on immune gene analysis.
Xing P; Jiang Z; Liu Y
BMC Cancer; 2022 Aug; 22(1):926. PubMed ID: 36030212
[TBL] [Abstract][Full Text] [Related]
15. Exploring the Shared Gene Signatures and Molecular Mechanisms between Bladder Urothelial Carcinoma and Metabolic Syndrome.
Li C; Wan Z; Deng Q; Li Z; Wang Y
Arch Esp Urol; 2023 Oct; 76(8):605-621. PubMed ID: 37960960
[TBL] [Abstract][Full Text] [Related]
16. MTHFD2 promotes PD-L1 expression via activation of the JAK/STAT signalling pathway in bladder cancer.
Li L; Zhang Y; Hu W; Zou F; Ning J; Rao T; Ruan Y; Yu W; Cheng F
J Cell Mol Med; 2023 Oct; 27(19):2922-2936. PubMed ID: 37480214
[TBL] [Abstract][Full Text] [Related]
17. High expression of
Lin B; Zhang T; Ye X; Yang H
Oncol Lett; 2020 Sep; 20(3):2840-2854. PubMed ID: 32782602
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation.
Wang X; Bai Y; Zhang F; Li D; Chen K; Wu R; Tang Y; Wei X; Han P
Front Immunol; 2023; 14():955949. PubMed ID: 37006317
[TBL] [Abstract][Full Text] [Related]
19. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
20. Identification of a basement membrane-related genes signature with immune correlation in bladder urothelial carcinoma and verification in vitro.
Li Y; Xu K; Zhang Y; Mao H; Qiu Q; Yan Z; Liu X; Du Y; Chen Z
BMC Cancer; 2023 Oct; 23(1):1021. PubMed ID: 37872487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]